Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lipella Pharmaceuticals Inc | LIPO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.725 | 04:00:35 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.725 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.64 - 2.71 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.725 | USD |
Lipella Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.5M | 6.25M | - | 450k | -4.62M | -0.74 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lipella Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LIPO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.712 | 0.7393 | 0.70 | 0.7146322 | 5,971 | 0.013 | 1.83% |
| 1 Month | 0.661 | 0.769 | 0.64 | 0.7135659 | 28,897 | 0.064 | 9.68% |
| 3 Months | 0.95 | 1.30 | 0.64 | 0.815014 | 63,516 | -0.225 | -23.68% |
| 6 Months | 1.27 | 1.31 | 0.64 | 0.8747592 | 38,491 | -0.545 | -42.91% |
| 1 Year | 2.28 | 2.71 | 0.64 | 1.98 | 215,892 | -1.56 | -68.20% |
| 3 Years | 7.02 | 7.72 | 0.64 | 2.53 | 336,161 | -6.30 | -89.67% |
| 5 Years | 7.02 | 7.72 | 0.64 | 2.53 | 336,161 | -6.30 | -89.67% |
Lipella Pharmaceuticals Description
| Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. |
